Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7665894 | 0.89 | LMNA (0.60) | MEN1KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL7671620 | 0.88 | LMNA (0.59) | MEN1KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL7673748 | 0.87 | ALDH1A1 (0.74) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4834530 | 0.87 | LMNA (0.74) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7673498 | 0.87 | LMNA (0.59) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL7663470 | 0.87 | LMNA (0.62) | ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL4832336 | 0.86 | MEN1 (0.62) | MEN1KMT2AALDH1A1TDP1LMNA | |
| SCHEMBL7670605 | 0.86 | CA1 (0.63) | MEN1KMT2AALDH1A1POLBTDP1 | |
| SCHEMBL7675070 | 0.86 | PRMT1 (0.68) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL7673893 | 0.86 | LMNA (0.61) | KMT2AALDH1A1MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | claimed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | claimed |
| US-7348017-B2 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1422224-B1 | DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN | SHISEIDO CO LTD (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422224-A1 | DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN | Shiseido Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| EP-0757984-B1 | Hydroxamic acid derivatives useful for inhibiting gelatinase | ONO PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-6177466-B1 | Sulfonylamino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| US-6022893-A | PREVENTION AND TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION OR EXCESS ACTIVATION OF GELATINASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-02-08 | — | — | US | disclosed |
| EP-0757984-A1 | Hydroxamic acid derivatives useful for inhibiting gelatinase | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | MMP1, MMP2, MMP3 | MEN1 4588/4885KMT2A 2099/4885ALDH1A1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.